Efficacy and safety of febuxostat for treatment of asymptomatic hyperuricemia among kidney transplant patients: A meta-analysis of observational studies.

Api ChewcharatYuan-Ting ChangCharat ThongprayoonAnthony CrisafioTarun BathiniMichael A MaoWisit Cheungpasitporn

Published in: Clinical transplantation (2020)

Among kidney transplant patients, treating hyperuricemia with febuxostat showed a higher odds of reaching the target of serum uric acid < 6 mg/dL compared with allopurinol without causing significant side effects including change in tacrolimus level, liver function, decline in renal graft function, and bone marrow function.

Keyphrases

uric acid
end stage renal disease
bone marrow
newly diagnosed
ejection fraction
chronic kidney disease
metabolic syndrome
prognostic factors
mesenchymal stem cells
replacement therapy
smoking cessation